Discover and read the best of Twitter Threads about #ASCO19VR
Most recents (3)
Here are my Top 5 #ASCO22 @ASCO myeloma abstracts. #ASCO22VR
Links to the full abstract. As in the past, I left out studies where similar results were already presented or published before. Top 5 based on new data, clinical impact & methodology
Thread with countdown👇
Links to the full abstract. As in the past, I left out studies where similar results were already presented or published before. Top 5 based on new data, clinical impact & methodology
Thread with countdown👇
#5 Risk adapted maintenance: Len for standard risk & Len plus Bortezomib for high risk gives outstanding results. #ASCO22 #ASCO22VR
Clinically important & updated data are excellent. @RujulParikh @SagarLonialMD @AjayNookaMD @WinshipAtEmory meetings.asco.org/abstracts-pres…
Clinically important & updated data are excellent. @RujulParikh @SagarLonialMD @AjayNookaMD @WinshipAtEmory meetings.asco.org/abstracts-pres…
#4 CAR-T targeting GPRC5D. Doubt if one BCMA approach fails another BCMA approach will give significant benefit. These treatments are incredibly expensive. We need immunotherapy options that target something besides BCMA. @ZJU_China
#ASCO22 #ASCO22VR meetings.asco.org/abstracts-pres…
#ASCO22 #ASCO22VR meetings.asco.org/abstracts-pres…
Here are my Top 5 #ASCO21 @ASCO myeloma abstracts. #ASCO21VR
I’ve listed them with links to the full abstract. @mtmdphd @Rfonsi1 @MayoMyeloma @chadinabhan @Mohty_EBMT @BldCancerDoc @szusmani @NBahlis @NoopurRajeMD @profghjackson @contirena1 @DusetzinaS
Thread for countdown👇
I’ve listed them with links to the full abstract. @mtmdphd @Rfonsi1 @MayoMyeloma @chadinabhan @Mohty_EBMT @BldCancerDoc @szusmani @NBahlis @NoopurRajeMD @profghjackson @contirena1 @DusetzinaS
Thread for countdown👇
#5 Daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd) for ultra high risk MM and plasma cell leukemia. A modern alternative to VDT-PACE. 94% response rate. @profghjackson @MyelomaUK #ASCO21VR #ASCO21
meetinglibrary.asco.org/record/195431/…
meetinglibrary.asco.org/record/195431/…
#4 Financial difficulty in patients with multiple myeloma. 20% of patients reported financial difficulties in 1 year. Glad this is being studied. I do think this is an underestimate. @ALLIANCE_org @theNCI @contirena1 #ASCO21VR #ASCO21
meetinglibrary.asco.org/record/195456/…
meetinglibrary.asco.org/record/195456/…
Here are my Top 5 #ASCO19 @ASCO myeloma abstracts. #ASCO19VR
I’ve listed them with links to the full abstract. @mtmdphd @myelomaMD @MyelomaTeacher @MayoMyeloma @NorthTxMSG @Mohty_EBMT @BldCancerDoc @DrAnasYounes @DrMiguelPerales @JohnPLeonardMD
See thread for countdown! 👇
I’ve listed them with links to the full abstract. @mtmdphd @myelomaMD @MyelomaTeacher @MayoMyeloma @NorthTxMSG @Mohty_EBMT @BldCancerDoc @DrAnasYounes @DrMiguelPerales @JohnPLeonardMD
See thread for countdown! 👇
#5 Isatuximab-Pom-Dex vs Pom-Dex in relapsed refractory myeloma. First phase III with this drug. May lead to FDA approval and provide alternative to Dara (?compete on cost) @DanaFarber @sanofi @mtmdphd @grpetersen1 #ASCO19 #ASCO19VR
abstracts.asco.org/239/AbstView_2…
abstracts.asco.org/239/AbstView_2…
#4 IMWG Risk stratification for Smoldering Myeloma. ~2000 patient study defines intermediate & high risk smoldering myeloma with simple parameters. Of importance: identifies candidates for early therapy. @mvmateos @myelomaMD @IMFmyeloma #ASCO19 #ASCO19VR
abstracts.asco.org/239/AbstView_2…
abstracts.asco.org/239/AbstView_2…
